Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
Descriptor ID |
D047428
|
MeSH Number(s) |
D27.505.519.389.755
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 1 | 1 | 2 |
1997 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 2 | 0 | 2 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 0 | 3 | 3 |
2004 | 4 | 9 | 13 |
2005 | 9 | 13 | 22 |
2006 | 42 | 22 | 64 |
2007 | 44 | 33 | 77 |
2008 | 42 | 33 | 75 |
2009 | 60 | 30 | 90 |
2010 | 72 | 37 | 109 |
2011 | 80 | 41 | 121 |
2012 | 78 | 53 | 131 |
2013 | 91 | 46 | 137 |
2014 | 83 | 45 | 128 |
2015 | 95 | 46 | 141 |
2016 | 81 | 42 | 123 |
2017 | 93 | 54 | 147 |
2018 | 80 | 37 | 117 |
2019 | 77 | 52 | 129 |
2020 | 59 | 42 | 101 |
2021 | 66 | 47 | 113 |
2022 | 12 | 80 | 92 |
2023 | 7 | 88 | 95 |
2024 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Degradation trumps mutations in cancer. Science. 2024 Feb 02; 383(6682):480-481.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.
-
Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer. J Neurooncol. 2024 Jan; 166(1):39-49.
-
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406.
-
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.
-
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 12 15; 83(24):4161-4178.
-
Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.